Conjunctisan A & eye aging – What Can Be Done?

Written by MASON, PhD., Robert

Over the past few years numerous attempts have been made to prevent and reverse age related disorders of vision, particularly those associated with cataracts, using conventional methods of treatment.

No pharmaceutical preparation could be clinically proven to provide an absolutely reliable therapy. More recently however, research work in the field of molecular biology and careful, detailed studies, carried out over a total of 12 years, has yielded very encouraging results.

Age related disorders of vision and cataract can indeed be influenced, if they are treated with special organ lysates, derived from various tissues of the eye, as contained in the German company VitOrgan product called Conjunctisan A ®.

Cataract is mainly due to disturbed energy exchange, impaired proteins and cross-linking of protein molecules. As the protoplasmic cellular factors of Conjunctisan A ® improve the supply of energy, they have a favorable influence on lenticular transparency.

Numerous clinical reports have presented convincing evidence to confirm the efficiency of Conjunctisan A ®, a success rate in improvement of vision for 65% of Cataract sufferers. Previously it was thought that senile Cataract and associated disorders of vision could only be treated by surgery. This has now been superseded in the findings of the long-term study, on 356 eyes treated with Conjunctisan A ®.

The ability of Conjunctisan A ® to improve the condition of vision has benefits on its ability to prevent deterioration and prolong the normal vision in older individuals. As Conjunctisan A ® has now been available in Europe for over 12 years, it has been tolerated extremely well, even in prolonged usage there are no known side effects.


1. Fuchs J, “Conservative treatment of senile cataract with Conjunctisan A ®.” Klin. Mbl. Augenheilk, 175 (1979), 799-805.
2. Seifert J, Ganser R, Pfleiderer A, Brendel W, “Absorption and distribution of cytoplasmic organ lysates (Conjunctisan A ® eye-drops), following intraconjunctival application.” Klin. Mbl. Augenheilk, 175 (1979), 795-798.
3. Fuchs J, “The effect of Conjunctisan A ® eye-drops on cataracts.” Med. Monatsschrift, May 1975, Page 224-225.
4. Fuchs J, “Is it possible to influence a senile cataract with drugs?” Med. Klinik 78, (1983), 171-174.